Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01713855 · ClinicalTrials.gov registry record · NA
Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura
A NA study of Immune Thrombocytopenic Purpura and Idiopathic Thrombocytopenic Purpura, sponsored by Neufeld, Ellis J, MD, PhD.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 3
- Study locations
NCT01713855: Completed NA study of Immune Thrombocytopenic Purpura and Idiopathic Thrombocytopenic Purpura, sponsored by Neufeld, Ellis J, MD, PhD.
NCT01713855 is a NA study of Immune Thrombocytopenic Purpura and Idiopathic Thrombocytopenic Purpura that has completed, run by Neufeld, Ellis J, MD, PhD. The registered enrollment target is 10 participants, below the 132-participant average among 3 other Immune Thrombocytopenic Purpura trials with a reported enrollment target (92% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01713855, a NA study of Immune Thrombocytopenic Purpura and Idiopathic Thrombocytopenic Purpura, has completed, sponsored by Neufeld, Ellis J, MD, PhD.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine how children with a history of severe, chronic Idiopathic Thrombocytopenic Purpura (ITP) who were treated with rituximab might respond to vaccines. Eligible patients are previously or currently enrolled in a study entitled "Open Label, Phase I/II Trial of Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura in Children and Adolescents" and have decided to obtain an inactivated influenza vaccination. These patients will be invited to provide one blood sample prior to vaccination and a second sample following vaccination to quantify immune response to vaccination.
Conditions Studied
Interventions
- BIOLOGICAL Inactivated Trivalent Influenza vaccine
Study Locations (3)
California
- University of California, Los Angeles - Los Angeles
Georgia
- Emory University School of Medicine - Atlanta
Massachusetts
- Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2004-10 |
| Est. Completion | 2006-03 |
| Phase | NA |
What the finished NCT01713855 record still lists
NCT01713855 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 132-participant average among 3 other Immune Thrombocytopenic Purpura trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Immune Thrombocytopenic Purpura appearing as the primary indexed condition, and to 1 intervention - of which Inactivated Trivalent Influenza vaccine is the first listed.
NCT01713855 reports a single indexed study location in California, Georgia, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01713855 about?
NCT01713855 is a clinical study titled "Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura". The purpose of this study is to determine how children with a history of severe, chronic Idiopathic Thrombocytopenic Purpura (ITP) who were treated with rituximab might respond to vaccines. Eligible patients are previously or currently enrolled in a study entitled "Open Label, Phase I/II Trial of Ri...
What is the current status of trial NCT01713855?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2004-10. Estimated completion is 2006-03.
What conditions does trial NCT01713855 study?
This clinical trial studies the following conditions: Immune Thrombocytopenic Purpura, Idiopathic Thrombocytopenic Purpura.
What interventions are being tested in trial NCT01713855?
The interventions under investigation include: Inactivated Trivalent Influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01713855?
This trial is sponsored by Neufeld, Ellis J, MD, PhD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01713855 being conducted?
This trial has 3 study locations across California, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immune Thrombocytopenic Purpura
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
COMPLETED · Phase 3
-
Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
COMPLETED · Phase 3
-
An Epidemiological Study of Subjects With Immune Thrombocytopenic Purpura to Evaluate the Relationship Between Platelet Counts, Endogenous Thrombopoietin Levels, Endogenous Anti-Thrombopoietin Antibodies, and Selected Autoimmune Markers
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia